BioCryst CFO resigns, search for successor begins

Published 04/03/2025, 14:12
BioCryst CFO resigns, search for successor begins

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX), a company specializing in biological products with a market capitalization of $1.78 billion, announced the resignation of Chief Financial Officer Anthony Doyle. Mr. Doyle, who has been with the Durham, North Carolina-based company since April 2020, will step down from his role effective April 9, 2025. The announcement was made through a Form 8-K filing with the Securities and Exchange Commission on Monday.

During his tenure, Doyle has been credited with contributing significantly to the global launch of ORLADEYO and strengthening the company’s financial position, as evidenced by impressive 36% revenue growth to $450.71 million and a healthy current ratio of 2.63. BioCryst emphasized that his departure is not due to any disagreements on matters of operations, policies, or practices.

The company has expressed gratitude for Doyle’s dedicated service and extended well wishes for his future endeavors. To ensure a smooth transition, Doyle will continue in his current capacity until his effective resignation date. Meanwhile, BioCryst has initiated a search for a new CFO to take over the financial leadership of the organization.

This executive change comes at a time when BioCryst is approaching a critical phase of profitability, highlighting the importance of financial leadership in the company’s ongoing success. The information regarding this transition is based on the company’s recent SEC filing.

In other recent news, BioCryst Pharmaceuticals has reported a fourth-quarter 2024 revenue of $131.53 million, surpassing analyst estimates of $127.17 million and marking a 40.8% increase year-over-year. Despite exceeding revenue expectations, the company reported a larger-than-expected loss per share of $0.13, compared to the anticipated $0.07 loss. BioCryst has raised its 2025 revenue guidance for Orladeyo, projecting global net revenue between $535 million and $550 million, attributing this to increased affordability for Medicare patients under the Inflation Reduction Act. JMP Securities and H.C. Wainwright have maintained their positive ratings on BioCryst, with price targets of $18.00 and $30.00, respectively. Piper Sandler also reaffirmed an Overweight rating with a $23.00 target, highlighting BioCryst’s strategic pipeline investments and commercial potential. Analysts from Citizens JMP and Piper Sandler noted BioCryst’s updated 2025 revenue guidance, with projections ranging from $560 million to $575 million. The company is focusing on promising developments in its rare disease pipeline, including BCX17725 for Netherton syndrome. Despite the EPS miss, analysts like JPMorgan’s Jessica Fye remain optimistic, citing the upward revenue guidance as a positive indicator for the company’s growth trajectory.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.